Diagnosis and Management of Acute Rejection

  • F. M. Wagner
  • H. Shennib


Lung transplantation is currently offered as treatment to a variety of end-stage pulmonary diseases such as emphysema, interstitial pulmonary fibrosis, cystic fibrosis, and pulmonary hypertension. The most recent Registry report of the International Society for Heart and Lung Transplantation reveals that more than 4000 lung transplants have been performed worldwide, with a 1-year and 5-year survival of 75% and 50% respectively[1].


Acute Rejection Lung Transplant Rejection Episode Obliterative Bronchiolitis Lung Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hosenpud J. The International Society of Heart and Lung Transplantation the 15th Annual Registry Report. 1995. J Heart Lung Transplant. 1995;13:561–70.Google Scholar
  2. 2.
    Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. The potential role of dendritic cells in bronchiolitis obliterans in heart lung transplantation. Ann Thorac Surg. 1990;49:424–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Griffith BP, Hardesty RL, Armitage JM et al. Acute rejection of lung allografts with various immunosuppressive protocols. Ann Thorac Surg. 1992;54:846–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Kriett JM, Smith CM, Hayden AM et al. Lung transplantation without the use of antilymphocyle antibody preparations. J Heart Lung Transplant. 1994;13:915–23.Google Scholar
  5. 5.
    Prop J, Juijpers P, Wildevuur CRH. Lung allograft rejection in the rat. L Accelerated rejection caused by graft lymphocytes. Transplantalion. 1985;40:25.CrossRefGoogle Scholar
  6. 6.
    Prop J, Wildevuur CRH, Niewenhuuis P. Lung allograft rejection in the rat. II. Specific immunological properties of lung grafts. Transplantation. 1985;40:126.PubMedCrossRefGoogle Scholar
  7. 7.
    Prop J, Wildevuur CRH, Niewenhuuis P. Lung allograft rejection in the rat. III. Corresponding morphological rejection phase in various rat strain combinations. Transplantation. 1985;40:132.PubMedCrossRefGoogle Scholar
  8. 8.
    Yousem SA, Berry GJ, Brunt E et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1990;9:593–601.Google Scholar
  9. 9.
    Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of panel reactive antibodies and the donor-specific, crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol. 1993;1:60–65.CrossRefGoogle Scholar
  10. 10.
    Sleiman C, Mal H, Fournier M et al. Pulmonary reimplantation response in single-lung transplantation. Eur Respir J. 1995;8:5–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Yousem SA, Duncan SR, Ohori NP, Sonmez-Alpan E. Architectural remodeling of lung allografts in acute and chronic rejection. Arch Pathol Lab Med. 1992;116:1175–80.PubMedGoogle Scholar
  12. 12.
    Yousem SA, Paradis IL, Dauber JH et al. Pulmonary atherosclerosis in long-term human heart-lung transplant recipients. Transplantation. 1989;47:564.PubMedCrossRefGoogle Scholar
  13. 13.
    Whitehead B, Rees P, Sorensen K, Bull C et al. Incidence of obliterative bronchiolitis after heart-lung transplantation. J Heart Lung Transplant. 1994;13:903–8.Google Scholar
  14. 14.
    Stewart S. Pathology of lung transplantation. Sem Diagn Pathol. 1992;9:210.Google Scholar
  15. 15.
    Scott JP, Higenbottam TW. Clelland CA, Smyth RL, Wallwork J. The natural history of chronic rejection in heart-lung transplant recipients: a clinical, pathological and physiological review of 29 long-term survivors. Transplant Proc. 1990;22:1474–6.PubMedGoogle Scholar
  16. 16.
    Yousein SA, Dauber JA, Keenan R et al. Does histologic acute rejection in lung transplant allografts predict the development of bronchiolitis obliterans? Transplantation. 1991;52:306–9.CrossRefGoogle Scholar
  17. 17.
    Keenan RJ, Lega ME, Dummer S et al. Cytomegalovirus serologic status and post-operative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51:433.PubMedCrossRefGoogle Scholar
  18. 18.
    Scott JP, Higenbottam TW, Sharples L et al. Risk factors for obliterative bronchiolitis in heart-lung recipients. Transplantalion. 1991;51:813.CrossRefGoogle Scholar
  19. 19.
    Griffith BP, Paradis IL, Zeevi A et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg. 1988;208:371–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Fragomeni LS, Bonser RS, Jamieson SW, Cardiopulmonary transplantation: current practise. Transplant Int. 1992;1:103–8.CrossRefGoogle Scholar
  21. 21.
    Paradis IL, Duncan SR, Dauber JH et al. Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation. J Heart Lung Transplant. 1992;11:232–6.Google Scholar
  22. 22.
    Trulock EP, Ettinger NA, Brunt EM et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures. Chest. 1992;102:1049–54.PubMedGoogle Scholar
  23. 23.
    Shennib H, Nguyen D. Bronchoalveolar lavage in lung transplantation. Ann Thorac Surg. 1991;51:335–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Otulana BA, Higenbottam T, Scott J et al. Lung function associated with histologically diagnosed acute lung rejection and pulmonary infection in heart-lung recipients. Am Rev Respir Dis. 1990;142:3329–32.Google Scholar
  25. 25.
    Smyth RL, Higenbottam T, Scott JP, Wallwork J. Transplantation of the lungs. Respir Med. 1989;83:459–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Becker FS, Martinez FJ, Brunsting LA et al. Limitations of spirometry in detecting rejection after single-lung transplantation. Am J Respir Crit Care Med. 1994;150:159–66.PubMedGoogle Scholar
  27. 27.
    Herman SJ, Rappaport DC, Weisbrod GL et al. Single lung transplantation: imaging features. Radiology, 1989;170:89–93.PubMedGoogle Scholar
  28. 28.
    Bergin CJ, Catellino RA, Blank N et al. Acute lung rejection after heart-lung transplantation. Am J Roentgenol. 1990;155:23–7.Google Scholar
  29. 29.
    Anderson DC, Glazer HS, Semenkovich JW et al. Lung transplant edema: chest radiography after lung transplantation-the first 10 days. Radiology. 1995;195:275–81.PubMedGoogle Scholar
  30. 30.
    Medina LS, Siegel MJ, Glazer HS et al. Diagnosis of pulmonary complications associated with lung transplantation in children: value of CT vs histopathological studies. Am J Roentgenol. 1994;162:969 74.Google Scholar
  31. 31.
    Loubcyre P, Revel D, Delignetle A, Loire R, Mornex JF. High resolution computed tomographic findings associated with histologically diagnosed acute lung rejection in heart-lung transplant recipients. Chest. 1995;107:132–8.Google Scholar
  32. 32.
    Ikonen T, Sovijarvi A, Aarnio P et al. Radiospirometric assessment of changes in regional perfusion and ventilation/perfusion ratio during acute rejection in pigs after left lung transplantation. Transplant Proc. 1994;26: 1814.PubMedGoogle Scholar
  33. 33.
    Levine SM, Jenkinson SG, Bryan CL et al. Ventilation perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension. Chest. 1992;101:401–5.PubMedGoogle Scholar
  34. 34.
    Grossman RF, Frost A, Zanel N et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. N Engl J Med. 1990;322:727–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Wagner FM, Reichenspurner H, Rihl M et al. Diagnosis of pulmonary rejection. 6th Congress of European Society of Organ Transplantation in Rhodes, 1993;87:70 (abstract).Google Scholar
  36. 36.
    Selvaggi SM, Bronchoalveolar lavage in lung transplant patients. Acta Cytolog. 1992;36:674–79.Google Scholar
  37. 37.
    Tazelaar HD. Perivascular inflammation in pulmonary infections: implications (or the diagnosis of lung rejection. J Heart Lung Transplant. 1991;10:626–36.Google Scholar
  38. 38.
    Prop J, Waggenaar-Hilber JPA, Peterson AH, Wildevuur CRH. Characteristics of cells lavaged from rejecting lung allografts in rats. Transplant Proc. 1988;20:217–19.PubMedGoogle Scholar
  39. 39.
    Herlan D, Kormos R, Zeevi A et al. Dynamics of bronchoalveolar lavage in the canine lung transplant. Transplant Proc. 1988;20(Suppl. 1):832–4.PubMedGoogle Scholar
  40. 40.
    Gryzan S, Paradis IL, Hardesty RL et al. Bronchoalveolar lavage in heart-lung transplantation. J Heart Lung Transplant. 1985;4:414–16.Google Scholar
  41. 41.
    Zeevi A, Rahinovitch H, Paradis I et al. Lymphocyte activation in bronchoalveolar lavage from heart-lung transplant recipients. Transplant Proc. 1988;20:189–92.PubMedGoogle Scholar
  42. 42.
    Paradis I, Zeevi A, Duquesnoy R et al. Immunologic aspects of chronic lung rejection in humans. Transplant Proc. 1988;20(Suppl. 1):8l2–l4.Google Scholar
  43. 43.
    Emeson EE, Norin AJ, Veith FJ. Lectin dependent cell mediated cytotoxicity. A new and simple method to quantitate cytotoxic T cell activity in dogs. Transplantation, 1982;33:365–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Norin AJ, Kamholz SL, Pinskecr KI, et al. Concanavalin A-dependent cell-mediated cytotoxicity in bronchoalveolar lavage fluid. Correlation with lung allongraft rejection in mongrel dogs during cyclosporin dose tapering. Transplantation. 1986;42:466–72.PubMedCrossRefGoogle Scholar
  45. 45.
    Rao PN, Zeevi A, Snyder J et al. Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation. J Heart Lung Transplant. 1994;13:958–62.PubMedGoogle Scholar
  46. 46.
    Ross DJ, Yeh AY, Nathan SD et al. Differential soluble interleukin-2R levels in bilateral bronchoalveolar lavage after single lung transplantation. J Heart Lung Transplant. 1994;13:972–9.PubMedGoogle Scholar
  47. 47.
    Scott JP, Fradet G, Smyth RL et al. Prospective study of transbronchial biopsies in the management of heart lung and single lung transplant recipients. J Heart Lung Transplant. 1991;10:626–36.PubMedGoogle Scholar
  48. 48.
    Starnes VA, Theodore J, Oyer PE et al. Pulmonary infiltrates after heart-lung transplantation: evaluation by serial transbronchial biopsies. J Thorac Cardiovasc Surg. 1989;98:945–50.PubMedGoogle Scholar
  49. 49.
    Magee MJ, Fitzgibbon L, Durham S et al. Thoracoscopy in the evaluation and treatment of lung transplant recipients, J Heart Lung Transplant. 1993;12(80Suppl.):A63.Google Scholar
  50. 50.
    Chapparo C, Maurer JR, Chamberlain DW, Todd TR. Role of open lung biopsy for diagnosis in lung transplant recipients: ten-year experience. Ann Thorac Surg. 1995;59:928–32.CrossRefGoogle Scholar
  51. 51.
    Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leucocytes of cyclosporin treated patients. Transplantation. 1995;59:1400–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Keown PA, Stiller CR, Carruthers G, Freeman D, Staweeki M. Cyclosporine: mechanism of action, measurement and clinical use. Br J Clin Pract. 1986;49:149–56.Google Scholar
  53. 53.
    Theodore J, Starnes VA, Lcwiston NJ. Obliterative hronehiolitis. Clin Chest Med. 1990;11:309–21.PubMedGoogle Scholar
  54. 54.
    Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED, Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Intern Med. 1987;107:300–4.PubMedGoogle Scholar
  55. 55.
    Lima O, Cooper JD, Peters WJ et al. Effects of methylprednisolone and azathioprine on bronchial healing following lung autotransplantation. J Thorac Cardiovasc Surg. 1981;82:211–15.PubMedGoogle Scholar
  56. 56.
    Calhoon JH, Grover FL, Gibbons WJ et al. Single lung transplantation: alternative indications and technique. J Thorac Cardiovasc Surg. 1991;101:816–25.PubMedGoogle Scholar
  57. 57.
    Shennib H, Massard G, Airway complications in lung transplantation. Ann Thorac Surg. 1994;57:506–11.PubMedCrossRefGoogle Scholar
  58. 58.
    Barr ML, Sanchez JA, Seche LA et al. Anti-CD3 monoclonal antibody induction therapy. Immunologic equivalency with triple drug therapy in heart transplantation. Circulation. 1990;82(5Suppl.):IV–291–4.Google Scholar
  59. 59.
    Hammond EH, Wittwer CT, Greenwood J et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776–82.PubMedCrossRefGoogle Scholar
  60. 60.
    Calhoon JH, Nichols L, Davis R et al. Single lung transplantation. Factors in post-operative cytomegalovirus infection. J Thorac Cardiovasc Surg. 1992;103:21–6.PubMedGoogle Scholar
  61. 61.
    Yousem SA. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol. 1993;17:491–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Armitage JM, Flicker FJ, Kurland G et al. Pediatric lung transplantation: the years 1985 to 1992 and the clinical trial of FK506. J Thorac Cardiovasc Surg. 1993;105:337–46.PubMedGoogle Scholar
  63. 63.
    Hosenpud JD, Hershberger RE, Ratkovec RR et al. Methotrexate for the treatment of patients with multiple episodes of acute cardiac allograft rejection. J Heart Lung Transplant. 1992;11:739–45.PubMedGoogle Scholar
  64. 64.
    Hutter JA, Despins P, Higenbottam T, Stewart S, Wallwork J. Heart-lung transplantation: better use of resources. Am J Med. 1988;85:4–11.PubMedCrossRefGoogle Scholar
  65. 65.
    DeHovos A, Chamberlain D, Schwartzman R et al. Prospective assessment of a standardized pathologic grading system for acute rejection in lung transplantation. Chest. 1993;103:1813–18.Google Scholar
  66. 66.
    Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant. 1994;13:514–19.PubMedGoogle Scholar
  67. 67.
    Wagner FM, Reichenspurner H, Ueberfuhr P et al. How successful is OKT3 therapy for steroid resistant acute rejection episodes after heart transplantation? Transplantation. 1994;13:444–50.Google Scholar
  68. 68.
    Parlevliet KJ, Schellekens PT. Monoclonal antibodies in renal transplantation: a review. Transplant Int. 1992;5:234–46.CrossRefGoogle Scholar
  69. 69.
    Mochon M, Kaiser B, Palmer A et al. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants. Ped Nephrol. 1993;7:259–62.CrossRefGoogle Scholar
  70. 70.
    Abouna GM, al-Ahdullah IH, Kelly-Sullivan et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing fixed daily dose with dose adjustment according to T cell monitoring. Transplantation. 1995;59:1564–8PubMedCrossRefGoogle Scholar
  71. 71.
    Hunt SA, Strober S, Hoppe RT, Stinson EB. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant. 1991;10:211–16.PubMedGoogle Scholar
  72. 72.
    Evans MA, Schomberg PJ, Rodeheffer J et al. Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clin Proc. 1992;67:785–90.PubMedGoogle Scholar
  73. 73.
    Kirklin JK, George JF, McGiffin C et al. Total lvmphoid irradiation: Is there a role in pediatric heart transplantation? J Heart Lung Transplant. 1993;12:S293–300.PubMedGoogle Scholar
  74. 74.
    Lindholm A, Kahan BD. Influence of cyclosporin pharmacokineties, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205–18.PubMedCrossRefGoogle Scholar
  75. 75.
    Kovarik JM, Mueller EA, van Brce JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation a multicenter investigation in kidney transplant patients. Transplantation. 1994;58:658.PubMedCrossRefGoogle Scholar
  76. 76.
    Kahan BD, Dunn J, Fitts C et al. Reduced inter-and intrasubject variability in cyclosporin pharmacokinetics in renal transplant recipients treated with microemulsion formulation in conjunction with fasting low fat meals, or high fat meals. Transplantation. 1995;59:505–11.PubMedGoogle Scholar
  77. 77.
    Niese D. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sundimmune Neoral Study Group. Transplant Proc. 1995;27:1849–56.Google Scholar
  78. 78.
    Keown PA, Lawen JG, Landsberg D et al. Economic analysis of Sandimmune Neoral in Canada in stable renal transplant patients. Transplant Proc. 1995;27:1845–8.PubMedGoogle Scholar
  79. 79.
    US Multicenter FK 506 Liver Study Group. A comparison of lacrolimus (FK506) and cyclosporin for immunnsuppression in liver transplantation. N Engl J Med. 1994;331:1110.CrossRefGoogle Scholar
  80. 80.
    Jordan ML, Shapiro A, Vivas CA et al. FK506 ‘rescue’ for resistant rejection of renal allografts under primary cyclosporin immunosuppression. Transplantation. 1994;57:860–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Griffith BP, Bando K, Hardesty RL et al. Prospective randomized trial of FK506 versus cyclosporin after human pulmonary transplantation. Transplantation. 1994;57:848–51.PubMedCrossRefGoogle Scholar
  82. 82.
    Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate Mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 1994;13:57l–82.Google Scholar
  83. 83.
    Klintmalm GB, Ascher NL, Busuttil RW et al. RS-61443 for treatment of resistant human liver rejection. Transplant Proc. 1993;25:697.PubMedGoogle Scholar
  84. 84.
    Deierhoi MH, Sollinger HW, Diethelm AG, Belzer FO, Kauffmann RS. One year follow-up results of a phase-I trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc. 1993;25:693–4.PubMedGoogle Scholar
  85. 85.
    Soliinger HW, Belzer FO, Deierhoi MH et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg. 1992;216:5l3–9.Google Scholar
  86. 86.
    Gregory CR, Huang X, Pratt RE et al. Transplantation with rapamycin and mycophenolic acid reduces intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655–61.PubMedCrossRefGoogle Scholar
  87. 87.
    Bando K, Paradis IL, Simlio S et al. Oblilerative bronchiolitis alter lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg. 1995;110:4–14.PubMedCrossRefGoogle Scholar
  88. 88.
    Anguita M, Lopez-Rubio F, Arizon JM et al. Repetitive nontreated episodes of grade I B or 2 acute rejection impair long-term cardiac graft function. J Heart hung Transplant. 1995;14:452–60.Google Scholar
  89. 89.
    Griffith BP, Hardesty RL, Armilage JM et al. A decade of lung transplantation. Ann Surg. 1993;218:310–20.PubMedCrossRefGoogle Scholar
  90. 90.
    Starzl TE, Demetris AJ, Trucco M et al. Chimerism after liver transplantation for Type IV glycogen storage disease and Type I Gaucher’s disease. N Engl J Med. 1993;328:745–9.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • F. M. Wagner
  • H. Shennib

There are no affiliations available

Personalised recommendations